Background
Methods
Patients and controls
Gender (male/female) | 210 (54%)/195(46%) |
Mean age (years ± SD)* | 47 ± 16 |
Type of psoriasis
| |
Vulgaris | 324 (80%) |
Palmoplantar | 49 (12%) |
Guttate | 16 (4%) |
other | 16 (4%) |
Cw6+ | 158 (39%) |
Affected relatives (familial Ps) | 219 (54%) |
Early-onset psoriasis#
| 243 (60%) |
Mean age (years ± SD)* | 34 ± 14 |
Cw6+ | 124 (51%) |
Late-onset psoriasis#
| 162 (40%) |
Mean age (years ± SD)* | 59 ± 9 |
Cw6+ | 34 (21%) |
Non-severe Ps (PASI < 10)* | 243 (60%) |
Severe Ps (PASI ≥ 10)* | 162 (40%) |
Arthritis | 89 (22%) |
Non-Arthritis | 316 (78%) |
LCE3C_LCE3B-del genotyping
SNP rs412788 genotyping
LCE3B/3C mutation screening
Statistical analysis
Results
LCE3C_3B del frequencies
LCE3 genotypes | Alleles | ||||
---|---|---|---|---|---|
II | ID | DD | D | I | |
Controls (n = 400) | 60 (15) | 196 (51) | 144 (36) | 493 (0.61) | 307 (0.39) |
Total patients (n = 405) | 52 (13) | 204 (50) | 149 (37) | 502 (0.62) | 308 (0.38) |
Psor. Vulgaris (n = 324) | 30 (9) | 157 (49) | 137 (42) | 431 (0.67) | 217 (0.33) |
Familial Ps (n = 221) | 32 (14) | 113 (51) | 76 (34) | 265 (0.60) | 177 (0.40) |
Sporadic Ps (n = 184) | 20 (11) | 91 (50) | 73 (39) | 237 (0.64) | 131 (036) |
Early onset Ps (n = 243) | 32 (13) | 124 (51) | 87 (36) | 298 (0.61) | 188 (0.39) |
Late onset Ps (n = 162) | 20 (12) | 77 (48) | 65 (40) | 207 (0.64) | 117 (0.36) |
Non Severe Ps (n = 243) | 28 (11) | 126 (52) | 89 (37) | 304 (0.63) | 182 (0.37) |
Severe Ps (n = 162) | 24 (15) | 78 (48) | 60 (37) | 198 (0.61) | 126 (0.39) |
Arthritis (n = 83) | 8 (10) | 49 (59) | 26 (31) | 101 (0.61) | 65 (0.39) |
Non arthritis (n = 322) | 44 (14) | 155 (45) | 123 (41) | 401 (0.62) | 243 (0.38) |
Cw6 positive (n = 158) | 11 (8) | 81 (51) | 66 (42) | 213 (0.67) | 103 (0.33) |
Cw6 negative (n = 247) | 40 (16) | 123 (50) | 84 (34) | 291 (0.59) | 203 (0.41) |
Psor. Vulgaris Non arhritis (n = 274) | 25 (9) | 128 (47) | 121 (44) | 370 (0.68) | 178 (0.32) |